Adult transgenic mice with muscle-specific overexpression of insulin-like growth factor (IGF)-I have enlarged skeletal muscles. In this study, we; 1) characterized the development of muscle hypertrophy with respect to fiber type, age, and sex; 2) determined the primary anabolic process responsible for development of hypertrophy; and 3) identified secondary effects of muscle hypertrophy on body composition. Transgene expression increased with age and was present only in fibers expressing type IIB fast myosin heavy chain. Muscle masses were greater by 5 wk of age, and by 10 wk of age the differences were maximal despite continued transgene expression. Total DNA and RNA contents of the gastrocnemius muscle were greater for transgenic mice than for nontransgenic littermates. The differences were maximal by 5 wk of age and preceded the increase in protein mass. The accelerated protein deposition ceased when the protein/DNA ratio attained the same value as in nontransgenic controls. Despite localization of IGF-I expression to muscle without changes in plasma IGF-I concentrations, genotype also modified the normal age and sex effects on fat deposition and organ growth. Thus, enhanced DNA accretion by IGF-I was primarily responsible for stimulating muscle growth. In turn, secondary effects on body composition were incurred that likely reflect the impact of muscle mass on whole body metabolism.
growth (5) . The expression of both peptides is elevated in skeletal muscle when there is accelerated growth, such as during early postnatal life (6) ; during work-induced muscle hypertrophy (7) ; and during regeneration after muscle or nerve injury (8, 9) . In these circumstances, the changes in IGF expression coincide with changes in the electrical and/or mechanical activity of the muscle. We and others have confirmed a direct autocrine/paracrine effect of IGF-I in vivo, by demonstrating that adult transgenic mice (SIS2) in which IGF-I is overexpressed in the differentiated skeletal muscle have significantly larger muscle mass (10) (11) (12) . The exact anabolic pathways stimulated by IGFs to mediate the growth response have not been clearly elucidated. Nonetheless, the in vitro evidence indicates that IGFs, either produced by the cells or added to the medium, accelerate most anabolic processes, including protein, RNA, and DNA accretion, and promote differentiation (5) . Further, it has been suggested that the specificity of IGF-I action, i.e., on cell replication versus differentiation, may depend on the stage of cell differentiation (13) .
IGF-I, acting through the IGF-1R, is believed to enhance skeletal muscle growth by stimulation of both satellite cell hyperplasia (14) and myofiber hypertrophy secondary to changes in protein synthesis and/or protein breakdown (15) . The quantitative contribution of each of these processes---and hence the relative importance of these mechanisms to the overall anabolic effect of the IGFs on muscle growth in vivo---is equivocal. In recent studies that used either a gene transfer technique (16) or direct infusion (17, 18) to increase local IGF-I, satellite cell replication and protein accretion were stimulated, but there was no increase in the mass-to-DNA ratio of the muscle to suggest a specific effect on protein accretion. However, direct infusion of IGF-I can increase muscle protein synthesis rates (15) . The effect of IGF-I on skeletal muscle protein degradation in vivo has been evaluated only indirectly (11, 19) and appears to be relatively insensitive.
To elucidate the mechanisms by which IGF-I regulates skeletal muscle growth, and the extent to which these processes may depend on age, we quantified the pattern of muscle growth in SIS2 mice in which a high level of IGF-I expression was sustained in skeletal muscle (10) . In view of the variable responses observed among muscles with different fiber compositions, we proceeded to determine the fiber type pattern of expression of the transgene (human IGF-I [hIGF-I]). To confirm these observations, we also measured hIGF-I mRNA and peptide expression, and the abundances of skeletal and cardiac α-actin, myoD, myogenin, and GLUT4 mRNAs. Finally, although the effect of the transgene on muscle growth was similar for males and females, the effect on body weight gain varied according to sex. Thus, parameters of body composition were assessed to identify potential mechanisms responsible for these secondary effects.
MATERIALS AND METHODS
Hemizygous SIS2 transgenic mice were mated. Pups were weighed within 24 h of birth, and litters were standardized to seven pups per dam. Genotype was determined when pups were 2 wk of age, by Southern analysis of DNA isolated from tail biopsy specimens. At 3 wk of age, pups were weaned, individually caged, and maintained under standard conditions. Water and feed (PicoLab Rodent Diet 20, Purina Mills, St. Louis, MO) were freely available.
The study was approved by the Animal Care and Use Committee of Baylor College of Medicine and was conducted in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals.
Experimental design
The transgenic mice were derived from the line (SK733 IGF-I 3'SK, abbreviated to SIS2) described by Coleman et al. (10) that expresses hIGF-I at high levels in the skeletal muscles. Male and female mice that were wild type (Wdt), hemizygous, or homozygous for the transgene were studied. At 5, 10, 20, and 32 wk of age (n = 7 or 8 per group), animals were killed, blood was collected and allowed to clot on ice, and serum was stored at −80 o C until analysis.
The gastrocnemius, soleus, extensor digitorum longus (EDL), and tibialis anterior (TA) muscles, and heart were dissected, weighed, frozen, and stored in liquid nitrogen. The liver, spleen, and kidneys were removed and weighed. The gastrointestinal tract from the pyloric sphincter to the rectum was removed, flushed, blotted, and weighed. The carcass (minus head, paws, and tail) was skinned and weighed after all visible fat and remaining viscera had been removed; carcass fat mass and fat-free mass (FFM; composed principally of bone and skeletal muscle) were then determined. All noncarcass body components were pooled and weighed, and their fat mass and FFM determined. Tibias were isolated and their lengths were measured to the nearest 0.1 mm with Vernier calipers.
The abundances of hIGF-I, skeletal and cardiac α-actin, myogenin, myoD, and GLUT4 mRNAs relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA or 18S rRNA in the skeletal muscles at 5 and 20 wk of age were determined. The gastrocnemius muscles were also analyzed for total protein, immunoreactive hIGF-I and endogenous rodent IGF-I (rIGF-I), RNA, and DNA concentrations. The serum from each mouse was analyzed for hIGF-I, rIGF-I, and insulin.
Crural muscles were collected from additional mice raised under identical conditions to determine by immunohistochemistry the fiber type distribution of transgenic hIGF-I expression.
Body composition and serum measurements
In a pilot study, SIS2 (n = 10) and Wdt mice (n = 10) were analyzed for total body water, fat, and FFM, as described previously (20) . The water content of the FFM was calculated to be 73.4 ± 0.2% for Wdt and 73.4 ± 0.4% for SIS2 mice, consistent with literature values for adult mice (21) . Thus, for the main study, we determined total body water from the weight lost on desiccation in a lyophilizer at 55 o C for 10 days. FFM was derived from the water content, and fat mass was calculated as the difference between body weight and FFM.
Insulin and total endogenous rIGF-I were measured by radioimmunoassay (RIA) with reagents provided in kit form (Linco, St. Louis, MO, and DSL, Webster, TX). Both kits contain antibodies and standards for the rat peptides that cross-react with the murine peptides. The rIGF-I antibody does not cross-react with hIGF-I. hIGF-I was measured by an immunoradiometric assay after acid/ethanol extraction (DSL); the hIGF-I-specific antibody does not cross-react with rIGF-I. For both peptides, the inter-and intra-assay coefficients of variation were less than 10%.
Skeletal muscle measurements
Soleus, EDL, TA, and gastrocnemius muscle mRNA abundances were measured when animals were 5 and 20 wk of age; muscles from six animals of each sex and genotype were pooled. Quantitative values of total protein, RNA, and DNA were determined for only the gastrocnemius muscle, and muscles from individual mice were analyzed.
Frozen muscles were powdered, and total RNA was extracted and fractionated on a 1% agarose, 0.66 M formaldehyde gel, as described previously (22) . The RNA was capillary transferred to a nylon membrane (GeneScreen, Dupont/New England Nuclear, Boston, MA), UV cross-linked, and baked at 80 o C for 1 h. The membrane was probed simultaneously for hIGF-I (23) and skeletal α-actin mRNA (24) by using cDNAs labeled by the random priming procedure; prehybridization and hybridization were carried out as described previously (10) . The intensity of the bands was quantified by using a phosphorimager (Molecular Dynamics, Sunnyvale, CA). The membranes were stripped by washing them at 95 o C in 0.1 M standard saline citrate and 0.1% sodium dodecyl sulfate and were reprobed for GAPDH mRNA by using a murine-specific cDNA (Ambion, Austin, TX) and finally for 18S rRNA by using a rat 18S rRNA cDNA (25) . A separate membrane was prepared for Northern analysis of myogenin (26) , myoD (27) , and cardiac α-actin (28), followed by GAPDH mRNA abundances, in the EDL, TA, and soleus muscles. GLUT4 (29) mRNA abundance was measured for only the gastrocnemius muscle.
IGF-I peptide concentration was determined from the gastrocnemius muscle of a subset of 5-wk-old (n = 8 SIS2, n = 4 Wdt) and 20-wk-old (n = 10 SIS2, n = 4 Wdt) mice as described previously (11) . The extracted peptide was quantified by RIA (rIGF-I) or immunoradiometric assay (hIGF-I) using reagents in kit form (DSL). Blanks for determination of nonspecific binding were generated by using tissues from species in which the IGF-I does not cross-react with the antibody in the assay (porcine for the rIGF-I, and rat for the hIGF-I). The sensitivity of the assay under the conditions described precluded the detection of the rIGF-I at concentrations less than 160 ng/g of tissue.
Quantitative determinations of total protein, RNA, and DNA concentrations were performed as previously described (30) .
Immunohistochemistry
Muscles were embedded in Tissue-Tek OCT compound (Miles, Elkhart, IN), frozen in liquid nitrogen-chilled isopentane, and cut into 10-µm-thick serial cross-sections in a cryotome at −20 o C. Dried serial sections were first blocked with unconjugated anti-mouse IgG (Vector Laboratories, Burlingame, CA) and then were incubated with one of five primary antibodies. Sections to be stained for hIGF-I were pretreated with 0.1 M acetic acid for 10 min. The monoclonal antibodies used were BA-D5, SC-71, BF-35, and BF-F3, which recognize the IA, IIA, IIA+IIB, and IIB myosin heavy chains, respectively, as characterized by Schiaffino et al. (31) , and GF-21L (Oncogene Research Products, San Diego, CA), which recognizes hIGF-I. The biotinylated secondary antibody/avidin/biotinylated horseradish peroxidase (ABC) system (Vector Laboratories) with 3,3-diaminobenzidine was used for visualization of the primary antibodies.
Statistics
Because of the variability in specific activities of cDNA probes between batches, only those membranes processed with the same batch of probe were statistically analyzed together. Thus, for skeletal α-actin mRNA, hIGF-I mRNAs, and 18S rRNA, the RNA from the EDL, TA, and soleus of 5-and 20-wk-old male and females were analyzed at the same time. The gastrocnemius muscle for the same mice was analyzed separately.
Values in the text are expressed as means ±1 SE when appropriate. For each independent outcome, the effects of genotype, sex, and age were analyzed as a single entity by ANOVA using a general linear model (MINITAB, version 12.21, State College, PA). Individual mice were nested in age, sex, and genotype, with age as a covariate and muscle as a repeated measure. In the figures, values for the pooled SD are shown. Interactions were evaluated and differences between groups were tested post-hoc by using Tukey's method. We established that for all parameters, there was no difference in the magnitude of the responses between hemizygous and homozygous transgenic animals. Thus, all transgenic data were pooled.
RESULTS

Pattern of transgene expression
A muscle-specific pattern of expression of the hIGF-I transgene was identified (Fig. 1) ; hIGF-I mRNA was expressed in muscles with a fast-twitch phenotype (EDL, TA, and gastrocnemius) but not in the soleus at 5 or 20 wk of age of either sex, despite the ubiquitous expression of the skeletal α-actin mRNA in all skeletal muscles. There was no difference in hIGF-I mRNA expression among fast-twitch SIS2 muscles at 5 wk of age, but at 20 wk of age the values were three to five times higher (age × muscle, P<0.005), and the increase was greatest for the EDL (P<0.01). The level of expression of hIGF-I peptide (986 ± 235 and 2005 ± 192 ng/g tissue at 5 and 20 wk of age, respectively) in the gastrocnemius muscle mimicked the increase in mRNA expression. The endogenous rIGF-I concentration was below the detectable limit of this assay.
There was no effect of genotype or sex on the relative abundance of the endogenous skeletal α-actin mRNA, regardless of muscle phenotype. However, the interaction between age and muscle was significant (P=0.053); among the fast-twitch muscles the relative abundance of skeletal α-actin mRNA increased approximately 50% with age (0.20 ± 0.03 at 5 wk to 0.30 ± 0.02 at 20 wk; P<0.05), whereas there was no change with age for the soleus. In contrast, cardiac α-actin mRNA was expressed at 5 wk of age in the EDL and TA of both SIS2 and Wdt mice (no difference between genotypes) but could not be detected at 20 wk of age; it was undetectable in the soleus at either 5 or 20 wk of age.
We next determined the specific fiber type pattern of expression of hIGF-I by immunohistochemistry; fiber type was defined on the basis of myosin heavy chain expression with isoform-specific antibodies. At all ages, hIGF-I was expressed only in fibers expressing the IIB myosin heavy chain isoform (Fig. 2) . At 5 wk of age, the overlap was not complete (that is, not all IIB fibers expressed hIGF-I), whereas there was almost complete coincidence of fiber type expression at 20 wk of age. The proportion of fibers that stained positive for IIB fibers at 20 wk of age was similar for SIS2 and Wdt mice and was similar for the gastrocnemius (62 ± 5%), EDL (65 ± 3%), and TA (71 ± 4%) muscles.
The relative abundances of myogenin and myoD mRNA showed muscle and genotype specificity (Fig. 3 ). For the EDL and TA, the relative abundance of myoD mRNA did not change with age, was higher in the SIS2 mice than in the Wdt controls (P<0.05), and was higher in the EDL than in the TA (P<0.05). In the soleus, there was a significant decrease in the relative abundance of myoD mRNA with age (P<0.05), and there was no effect of genotype. Myogenin mRNA (either per total RNA or relative to GAPDH mRNA abundance) was more abundant in the soleus than in the EDL or TA (P<0.001), and values for all muscles decreased between 5 and 20 wk of age (P<0.02). There was no effect of genotype on myogenin mRNA expression.
To establish the extent to which growth effects were due to autocrine/paracrine rather than endocrine effects of the hIGF-I, serum levels of IGF-I were determined (Fig. 4 ). There were measurable levels of hIGF-I in all SIS2 mice, but these were low relative to the endogenous peptide levels, and total serum IGF-I (human plus rodent) concentrations did not differ between genotypes. In both genotypes, total serum IGF-I decreased with age (P<0.001) and was higher in female than in male mice (P<0.05).
IGF-I inhibits insulin secretion from the pancreas (32) , and it has been demonstrated that in rodents the stimulation of muscle protein synthesis on administration of IGF-I can be mitigated unless the concurrent hypoinsulinemia is prevented (33) . Because differences in growth could result from these secondary effects of IGF-I, we also determined serum insulin concentration. There was no effect of genotype, age, or sex on serum insulin concentration: mean values for SIS2 and Wdt mice were 0.80 ± 0.08 (n = 81) and 0.78 ± 0.10 (n = 92) ng/ml, respectively.
Muscle growth
Muscle weights are shown in Fig. 5 . There was no effect of genotype on tibia length (P>0.8). Muscle weights increased with age and were heavier in male than in female mice. The weights of the fast-twitch muscles were significantly heavier in SIS2 mice, and for the gastrocnemius and TA, the difference between genotypes increased between 5 and 10 wk of age only (age × genotype, P<0.05). Soleus weights were similar across genotypes at 5 and 10 wk of age; at 20 wk the soleus was heavier in SIS2 females, and by 32 wk it was heavier in both male and female SIS2 mice.
Total protein, DNA, and RNA accretion values were significantly higher in SIS2 than in Wdt mice and greater in males than females (Fig. 6) . In SIS2 mice, the greater rate of protein accretion occurred only before 10 wk of age (age × genotype, P=0.055). Differences in total DNA and RNA contents between SIS2 and Wdt mice were maximal by 5 wk of age (P<0.001; age × genotype, NS). Total DNA increased until 10 wk of age, after which there was no further change. The protein/DNA ratio, a measure of the myonuclear domain size, was lower for SIS2 than Wdt mice at 5 wk of age. Subsequently, the protein/DNA ratio continued to increase, albeit more slowly, and was similar for SIS2 and Wdt mice. Total RNA decreased with age in males and remained unchanged in females (age × sex, P<0.01). The RNA/DNA and RNA/protein ratios (a measure of ribosomal abundance) decreased with age and were similar for both genotypes and sexes throughout the study. At 5 wk of age, the RNA/protein ratio tended to be higher in SIS2 mice (P< 0.07).
Body composition
SIS2 mice were heavier than Wdt mice (Fig. 7) . This effect of genotype was greater for female than male mice and changed with age (genotype × sex × age, P=0.06). The greater body weight gain in female than male SIS2 mice was due largely to differences in their accretion rates of total fat and fatfree noncarcass tissues (i.e., viscera and skin). SIS2 females deposited an amount of fat equivalent to that of their Wdt littermates, whereas between 5 and 10 wk of age the SIS2 males deposited less fat than did their Wdt littermates (P<0.04). In addition, in the females, total FFM accretion was greater for SIS2 than for Wdt animals (genotype × sex × age, P=0.06) because of a greater accretion of noncarcass weight after 5 wk of age. The pattern of fat-free carcass mass (which provides a good approximation of total body muscle mass) accretion was similar for males and females (genotype × sex, NS) and was greater in SIS2 mice than in Wdt mice. The higher rate of fat-free carcass mass gain in SIS2 mice continued only to 10 wk of age (genotype × age, P<0.002). The higher noncarcass tissue weight in SIS2 mice was due, in part, to greater visceral organ weights. The increase in gut and liver weights was proportional to the increase in the animals' metabolically active tissue mass. Thus, when expressed relative to FFM, the genotype differences in these organ weights were no longer significant (Fig. 8) . The increase in kidney weight was proportional to the change in FFM at 5 and 10 wk of age but thereafter grew proportionally less than the FFM; the response was similar for both males and females. Spleen weights were significantly greater in transgenic mice than in Wdt mice (P<0.001), were greater in female mice than male mice, and decreased with age, regardless of sex or genotype. Heart mass was disproportionately large in SIS2 mice; a more extensive evaluation of the cardiac response was reported previously (34) .
DISCUSSION
Local IGF-I acting in an autocrine/paracrine manner can stimulate the accretion of skeletal muscle mass. One approach to studying the mechanisms responsible for this response has been to generate transgenic mice in which high levels of IGF-I are continuously expressed by skeletal muscle (10, 12) . These previous reports have described the muscle phenotype exhibited by the adult animal, that is, once the hypertrophy is fully manifested. At this stage, therefore, the processes that were responsible for the enhanced growth are no longer operant, and differences between Wdt and transgenic animals in cellular characteristics reflect only those processes involved in the maintenance of the phenotype. The study we describe here was designed, therefore, to delineate the dynamic phase of the response and to assess those anabolic processes that are responsible for the enhanced growth. These highly quantitative observations also reflect the consequences at the tissue level of the responses that we had observed previously at the cellular level (35) . In addition, given the metabolic significance of the skeletal musculature, we wished to identify whether the changes in muscle mass had secondary effects on the growth of other body components.
Muscle growth pattern of SIS2 mice reflected fiber type-specific expression of the transgene
The growth patterns of individual muscles suggested a fiber type specificity in the expression of the transgene: at 5 and 10 wk of age, enhanced muscle growth was restricted to only fast-twitch muscles. The increased growth rates of these muscles in the SIS2 mice were not sustained beyond 5 wk of age in the EDL, or after 10 wk of age in the TA and gastrocnemius muscles. The soleus, a predominantly slow-twitch muscle, showed a much delayed and sex-specific response.
The expression pattern of the hIGF-I mRNA and peptide only partially explains the muscle growth patterns. Despite the ubiquitous distribution of skeletal α-actin in skeletal muscle, the immunohistochemistry results clearly showed that the expression of the transgene was restricted to type IIB fibers. This distribution explains, therefore, the muscle-specific pattern of response before 20 wk of age. Moreover, because in the mature muscle myoD mRNA is expressed preferentially by glycolytic fibers (36) , its higher abundance in the EDL and TA of SIS2 mice independently suggests the preferential hypertrophy of fast-twitch fibers in SIS2 mice. Given that skeletal α-actin expression is not restricted to fiber type, we questioned whether this response was due to an IGF-Iinduced conversion toward type IIB fibers, or to a function of the promoter. The first possibility is unlikely because the proportion of fibers expressing IIB myosin heavy chain at 20 wk was similar regardless of genotype. Moreover, we never observed hIGF-I peptide expression in fibers that were not IIB; rather, the reverse was true at 5 wk of age. Thus, these findings indicate that the 622-bp promoter/5'-untranslated region fragment of the chick skeletal α-actin gene used in the SIS2 construct must not contain regulatory elements that confer the widespread expression of the endogenous gene in skeletal muscle (although they did permit expression in cardiac muscle; see ref 34) . The developmental pattern of hIGF-I transgene expression likely reflects differences in the developmental programs of the α-actin genes (which would dictate the expression of the transgene) versus the myosin heavy chain genes (used to define the fiber types), as has been shown for other gene families (37, 38) . Indeed, cardiac α-actin was detectable in the predominantly fast-twitch muscles at 5 wk but not at 20 wk of age, whereas immature myosin isoforms would no longer be detectable at 5 wk (39). Moreover, it has been demonstrated that the expression of transgenes driven by constructs that contain only part of the skeletal α-actin promoter may be delayed more than the expression of the endogenous skeletal α-actin gene (40) .
Among the responsive muscles, the greater acceleration in growth rate in SIS2 mice was confined to the period before 10 wk of age. This cessation in responsiveness cannot be attributed to decreased expression of the transgene because the expression of both hIGF-I mRNA and peptide increased with age, an observation corroborated by Renganathan et al. (41) . This increase in expression with age also is consistent with the immunohistochemistry that showed an increase in the number of fibers expressing the transgene between 5 and 20 wk in responsive muscles, and the developmental decrease in cardiac α-actin mRNA expression, which would be replaced by skeletal α-actin.
The soleus was positive for only type I and IIA myosin heavy chain and did not express the transgene. Nonetheless, at 20 wk of age in females and at 32 wk of age in both males and females, the soleus mass was greater in SIS2 mice. Although we cannot exclude a paracrine effect, the hypertrophy of the soleus likely occurred in response to the greater load bearing that resulted from the increased body weight of the transgenic animals. The response of male and female SIS2 mice is commensurate with the difference in the patterns of body weight gain of the two sexes; i.e., weight gain in females was earlier and greater than that in males. Similar responses by the soleus to overload have been observed in young rats in which rates of weight gain were controlled experimentally by altering food intake (42), or in mice when external weights were used to increase body weight (43) .
Mechanism of enhanced muscle growth
Implicit to this discussion is the assumption that the changes in muscle DNA content reflect changes in the number of myonuclei (including satellite cell nuclei). Although this is not strictly correct, it has been demonstrated for rat skeletal muscle that the proportion of myonuclei to total nuclei present from birth to old age does not change (44) , despite the significant changes that occur in muscle size, structure, and function during postnatal life. Thus, it is generally accepted that an increase in the total DNA content in skeletal muscle provides an index of the increase in the number of myonuclei in the muscle, which is dependent on satellite cell replication (45) . Moreover, the response in total DNA that we report here is entirely consistent with the observations we have made previously on the replicative characteristics of satellite cells isolated from the hindlimbs of these mice (35) .
The temporal accretion patterns of nucleic acids and protein in the gastrocnemius muscle indicate that the enhanced accretion of DNA and RNA preceded the enhanced gain in protein. This resulted in a lower protein/DNA ratio in the muscles of SIS2 mice at 5 wk of age. Protein accretion, however, continued to 10 wk of age and was greater for the SIS2 mice than for the Wdt mice, thereby enabling the protein/DNA ratio, an index of myonuclear domain size, to attain control values (46) . Thereafter, the values remained similar and continued to increase with age. This finding is entirely consistent with our observations that the proliferative capacity of satellite cells isolated from SIS2 mice is higher than that of cells from Wdt mice at 1 month of age, but not at 12 and 18 months of age (35) .
Despite the continued presence of a high local concentration of hIGF-I and the continued accretion of nuclei beyond 5 wk of age, the period of accelerated DNA accretion in the SIS2 mice was restricted. Indeed, for the gastrocnemius muscle the difference in total DNA content was already maximal by 5 wk of age. In additional preliminary studies, we have determined that the difference in muscle size between Wdt and SIS2 littermates begins to emerge between 2 and 3 wk of age, presumably when endogenous muscle IGF levels decrease. Thus, there appears to be a narrow time window during which DNA accretion was responsive to the presence of IGF-I. There are several possible explanations for the limited nature of this response. The binding capacity of IGF-I to its receptor maybe mitigated by increased production of IGF binding proteins (IGFBPs); the number of type 1 IGF receptors may be down-regulated; and/or activities of the intracellular pathways that transmit the IGF signal to the nucleus could be attenuated.
The principal IGFBPs expressed by mature skeletal muscle in the mouse are IGFBP-5 and -6 and to a lesser extent IGFBP-4 (47) . Should the production of the IGFBPs be stimulated by IGF-I, the growth-promoting effect of IGF-I would become self-limiting. Although IGF-I increases expression of IGFBP-5 by muscle cells in vitro, this does not appear to occur in vivo (12, 48) . IGFBP-6 has a low binding affinity for IGF-I, and changes in its expression are unlikely to alter the availability of IGF-I to its receptor (49) . In the mouse, there is little (47) , if any (50), expression of IGFBP-4 by skeletal muscle. There are few data on the response of IGFBP-4 production to increases in local IGF-I. However, in response to stimuli that are trophic for skeletal muscle, such as loading (51) or anabolic steroids (52), IGFBP-4 expression is down-regulated, thereby facilitating the interaction of IGF-I and cell surface receptors. On the basis of these data, together with the observation that certain intracellular actions of IGF-I were sustained throughout the study, including the expression of GLUT4 mRNA (an IGF-responsive gene; see ref 53) , it seems unlikely that changes in IGFBP production contributed significantly to the limited growth response.
Continuous exposure to high levels of ligand often results in the down-regulation of its receptor or signaling through the receptor. However, we previously demonstrated that the number of receptors was similar in muscle satellite cells of SIS2 and Wdt littermates at 1 and 12 months of age, and also that autophosphorylation of the receptor in response to ligand was unaltered (35) . In contrast, downstream signaling from the IGF-1R to Akt, measured as Akt phosphorylation, remained slightly enhanced in SIS2 satellite cells in response to constant, higher IGF-I exposure for 12 months. Although the enhanced expression of GLUT4 mRNA in SIS2 mice of all ages further suggests that signaling down this intracellular pathway by IGF-I persisted, the proliferative ability of the satellite cells from SIS2 mice was not correspondingly greater at 12 months of age (35) . These data suggest that stimulation of some branches of the signaling pathway by IGF-I and the responsiveness of other key regulators of cell division to such stimulation are not sustained indefinitely. Together with the observation that mature muscles can mount a positive growth response when their local IGF-I concentration is elevated (16, 54) , these data thus suggest that prolonged exposure to IGF-I results in a loss in the responsiveness of the pathways specifically responsible for IGF-I stimulation of nuclear division.
How does DNA effect enhanced protein accretion?
We have shown that in young animals the rates of protein deposition in skeletal muscle are primarily determined by the fractional synthesis rate of muscle proteins, and the maximum capacity for protein synthesis is dictated by ribosomal abundance (22, 30) . Indeed, in SIS2 mice, the rate of muscle protein accretion was greatest when total RNA concentration (comprised largely of rRNA) was highest, and this result was coincident with the period of most rapid cell replication, as indicated by the rate of DNA accretion. It is well known that ribosome biogenesis is most active when cells are rapidly dividing. Hence, we would anticipate rates of muscle protein synthesis to be greater in SIS2 than Wdt littermates only during the period of active DNA accumulation; we have preliminary data to support this. Presumably, the reduced rate of cell division beyond 5 wk of age precluded continued RNA accretion. Thus, once the maximal myonuclear domain size (protein/DNA ratio) was attained, enhanced muscle protein deposition in SIS2 mice would not be sustained. This mechanism that links accelerated protein deposition to satellite cell replication does not preclude separate effects of IGF-I on gene expression, as indicated by the higher abundance of GLUT4 mRNA. The latter could be sustained in the absence of cell division and hypertrophy.
Effect on body composition: organs and chemical
An unexpected observation of our study was the genotype × sex interaction for several parameters of body composition, fat in particular. Fat deposition was reduced in SIS2 males before 10 wk of age, i.e., when muscle growth was enhanced, but was the same in all females regardless of genotype. However, because of the greater FFM, all SIS2 mice were leaner than the Wdt controls when fat was expressed relative to body weight. From the energy balance point of view, the genotype × sex interaction for body fat indicates that during the period of enhanced growth, females were in a more positive energy balance than males. The greater gastrointestinal mass of SIS2 females than males at 10, 20, and 32 wk of age is indicative of greater food and, hence, energy intake (55). In 5-wk-old SIS2 males, however, the compromised fat deposition suggests that their food intake was insufficient to meet the greater energy costs of growth and maintenance incurred by higher rates of protein deposition. Nonetheless, once the rates of FFM accretion were equivalent for both genotypes, fat accretion also continued in parallel.
The SIS2 mice were also distinguished by larger spleens. These spleens were maximally bigger by 5 wk of age, and the difference was sustained thereafter. Although the transgene is not expressed in the spleen of adult animals (10), we cannot exclude that it was expressed in immature animals. The spleen and other lymphoid tissues are highly responsive to increases in circulating IGF-I, but there was no correlation in individual mice between spleen weight and total IGF-I value (or hIGF-I and rIGF-I separately) at any age. At this time, therefore, we have no ready explanation for this response.
CONCLUSIONS
These results support evidence from a variety of models of stimulated muscle growth that indicate that the primary trophic mechanism of IGFs on skeletal muscle growth is to enhance DNA replication, presumably that of the satellite cells. Stimulation of protein deposition lagged behind the increase in DNA accretion. The link between the two processes is uncertain, although the results, supported by data from other studies, suggest a link through stimulation of ribosome accretion. We also demonstrated a limited capacity of skeletal muscle to respond to persistent exposure to elevated levels of IGF-I, which may be explained by a diminution in the activity of the primary IGF-Iresponsive mechanism (or mechanisms).
The study also revealed that, despite the localized expression of IGF in skeletal muscle, the effects were not confined to this tissue. There were secondary effects on the growth of other organs and on the body composition of the animals as a whole. These effects could result from the increase in muscle mass and/or alterations in muscle metabolism incurred by the IGF-I-induced changes in gene expression. Furthermore, these secondary effects were modified by age and sex. The anabolic effects of IGF-I have made it an appealing candidate for gene therapy under conditions of muscle atrophy. However, our observations serve to underscore that caution must be exercised in evaluating such approaches, because even though expression can be localized by using appropriate constructs, the secondary effects incurred may not be predictable. Northern blots were performed of total RNA (10 µg) isolated from a pool (n = 6 per sex per genotype) of EDL, TA, gastrocnemius (Gastr), and soleus muscles of 5-and 20-wk-old mice. Blots were probed sequentially for hIGF-I, skeletal α-actin mRNA, and 18S rRNA. Cardiac α-actin mRNA was analyzed on a separate blot. The intensities of the mRNA bands of interest were expressed relative to 18S rRNA abundance. Each column is the average of values for male and female mice; pSD is the pooled standard; nm indicates not measured. The top panel shows that hIGF-I mRNA abundance increased with age in the EDL, TA, and Gastr muscles of SIS2 mice (*P<0.05), with the largest increase occurring in the EDL ( †P<0.01). hIGF-I mRNA was not detectable in RNA extracted from all muscles of Wdt mice, and from the soleus of SIS2 mice. The middle panel shows that skeletal α-actin mRNA abundance was not altered by genotype; it increased with age in EDL, TA, and Gastr muscles (*P<0.05) but not in the soleus. The bottom panel shows that cardiac α-actin mRNA was not detectable in the soleus at 5 wk, or in any of the muscles at 20 wk of age. The left panel shows a section incubated with the primary monoclonal antibody BF-F3, specific for type IIB myosin heavy chain. The right panel shows a section incubated with the primary monoclonal antibody GF-21L, specific for hIGF-I. Reactivity was visualized by using biotinylated secondary antibodies, followed by avidin/biotinylated horseradish peroxidase/diaminobenzidine treatment. Northern blots of total RNA were probed sequentially for myoD, myogenin, and GAPDH mRNAs. Each RNA sample was extracted from a pool of muscles (EDL, TA, or soleus) from six mice of each genotype, age, and sex. Each column is the average of values for male and female mice; pSD is the pooled SD. Expression of GLUT4 mRNA was determined for the gastrocnemius muscle and is shown separately for male and female mice. The top panel shows higher relative myoD mRNA abundance in EDL and TA muscles from SIS2 mice than in Wdt controls (*P<0.05) at 5 and 20 wk of age; values were higher in the EDL than in the TA ( †P<0.05). There was no effect of genotype on soleus myoD mRNA, but values decreased with age ( ‡P<0.05). The middle panel shows that relative myogenin abundance decreased with age in all muscles (*P<0.001) and was higher in the soleus than in EDL or TA ( †P<0.02). The bottom panel shows that GLUT4 mRNA expression was influenced by age (*P<0.001), genotype ( †P<0.001), and sex at 20 wk of age ( ‡P<0.001). For all muscles, age and sex effects were significant (P<0.001); there was an effect of genotype on the EDL (P<0.001), TA (P<0.01), and gastrocnemius (P<0.03) muscles, which varied with age for TA and gastrocnemius (genotype × age, P<0.01 and P<0.02, respectively). Genotype effects on the soleus were present at 20 wk of age (females only) and 32 wk of age (males and females) (genotype × age × sex, P<0.05). Values were significantly higher in SIS2 than in Wdt mice (P<0.001) and were greater in males than in females (P<0.001). Values are means ±1 SE (n = 7 or 8 for Wdt mice, and n = 14-16 for SIS2 mice). The bottom panel shows the protein/DNA ratio, which provides a measure of myonuclear domain size, and total RNA/DNA and RNA/protein, which provide measures of ribosomal abundance and protein synthetic capacity, respectively. There was no effect of sex; values are means ±1 SE (n = 14-16 for Wdt mice, and n = 28-32 for SIS2 mice). Protein/DNA was significantly lower in SIS2 mice than in Wdt littermates at 5 wk of age (P<0.001). There was no effect of genotype on RNA/DNA at any age. RNA/protein tended to be higher in 5-wk-old SIS2 mice (P<0.07). × sex, P<0.06 ). The bottom panel shows components of the FFM. Carcass weight (skeletal musculature and skeleton) was significantly higher in SIS2 mice (P<0.002). The viscera and skin component (includes all internal organs, skin, head, tail, and paws) was greater in SIS2 mice than in control mice (P<0.01); the difference was greater for females (genotype × sex, P<0.05). Values are means ±1 SE (SIS2: n = 13-16 per data point; Wdt: n = 7 or 8 per data point). 
